BIOINFOGATE’S OFF-X REACHES HALF MILLION SAFETY ALERTS

OFF-X has become the largest translational safety and toxicity intelligence portal for drugs and targets of pharmacological interest. Barcelona Launched in 2017, OFF-X has now reached 500,000 curated safety alerts corresponding to almost 15,000 targets of pharmacological interest and almost 14,500 drugs and biologics. Unexpected safety issues still constitute one...

Continue reading

VHIO AND BIOINFOGATE PARTNER TO ENHANCE SAFETY ASSESSMENT IN CLINICAL RESEARCH

Announced today, the Vall d´Hebron Institute of Oncology - Bioinfogate collaboration will validate the utility of the OFF-X translational safety intelligence portal in the design of novel clinical trials, including first-in-human studies. Barcelona The Vall d´Hebron Institute of Oncology (VHIO) and Bioinfogate have launched a collaborative agreement to analyze...

Continue reading

FDA AND BIOINFOGATE AGREE TO EXTEND THE MATERIAL TRANSFER AGREEMENT (MTA) TO ACCESS THE OFF-X TRANSLATIONAL SAFETY INTELLIGENCE PORTAL

The agreement aims to evaluate new approaches to enhance safety assessments of human pharmaceuticals and their associated molecular targets, supporting the FDA’s mission of protecting public health. Barcelona Under this MTA, the FDA has agency-wide access to Bioinfogate’s translational safety intelligence portal, OFF-X. The primary objective of...

Continue reading